Managed Care - November 2008 - (Page RSV12)

tal and NICU, pediatrician, parent, home care provider, and insurer is necessary to achieve optimal compliance. References AAP (American Academy of Pediatrics). Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics. 1998;102:1211–1216. AAP (American Academy of Pediatrics) Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 pt 1):1442–1446. AAP (American Academy of Pediatrics). Respiratory syncytial virus. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Redbook: 2006. Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, Ill.: American Academy of Pediatrics; 2006:560–566. Berger J, Fensterheim L, O’Rourke J, et al. The importance of Synagis compliance in preventing hospitalizations. Pediatr Acad Soc. 2003. Abstract 2646. «http://www.abstracts 2view.com/pasall/view.php?nu=PAS3L_443». Accessed Oct. 15, 2008. Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167:379–383. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-RSVbronchiolitis in children. Am J Respir Crit Care Med. 2008; 178:854–860. Carbonell-Estrany X, Quero J, and the IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20:874–879. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815–820. Frogel M, Nerwen C. Five year experience with a coordinated neonatal and general pediatric practice palvizumab program that increases compliance and prevents RSV hospitalizations of high risk patients. Presented at: Pediatric Academic Societies Meeting, May 1–4, 2004, San Francisco. Abstract 1136. Frogel M, Nerwen C, Cohen A, et al.; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28:511–577. Garrison MM, Christakis DA, Harvey E, et al. Systemic corticosteroids in infant bronchiolitis: A meta-analysis. Pediatrics. 2000;105:E44. Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J. 2004;23:318–322. Hand IL, Geiss DM, Noble LM, Shotkin AM. Respiratory syncytial virus (RSV) immunoprophylaxis in a high-risk urban population: a comparison of delivery strategies and outcomes. Pediatr Acad Soc. 2003. Abstract 1908. «http://www. abstracts2view.com/pasall/view.php?nu=PAS3L_1843». Accessed Oct. 15, 2008. Holman RC, Shay DK, Curns AT, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003;22:483–489. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143:S133–S141. IMpact RSV-Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants. Pediatrics. 1998;102:531–537. Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis. Arch Pediatr Adolesc Med. 1996;150:1166–1172. Law BJ, Wang EE, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics. 1997;99:E7. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806–814. McLaurin K, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1997–2002. Presented at: Pediatric Academic Societies Meeting, May 14–17, 2005, Washington. Abstract 3. Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for the prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J. 1999;18:223–231. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143(5 suppl):S150–S156. Shay DK, Holman RC, Newman RD, et al. Bronchiolitisassociated hospitalizations among US children, 1980–1996. JAMA. 1999;282:1440–1446. Shay DK, Holman, RC, Roosevelt, GE, et al. Bronchiolitisassociated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis. 2001;183:16–22. Simões EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(5 suppl):S118–S126. Speer, ME, Boron M, McLaurin K, et al.; Palivizumab Outcomes Registry Group. Delayed prophylaxis in children at high risk for RSV disease. Pediatr Acad Soc. 2005. Abstract 712. «http://www.abstracts2view.com/pasall/view.php?nu= PAS5L1_459». Accessed Oct. 15, 2008. Viswanathan M, King V, Bordley C, et al. Management of Bronchiolitis in Infants and Children. Evidence Report/ Technology Assessment No. 69. AHRQ Publication No. 03E014. Rockville, Md.: U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. January 2003. Disclosures: Michael P. Frogel, MD, has received grant and research support and consulting fees related to palivizumab from MedImmune, and serves on MedImmune’s speaker’s bureau. 12 MANAGED CARE / SUPPLEMENT http://www.abstracts2view.com/pasall/view.php?nu=PAS3L_443 http://www.abstracts2view.com/pasall/view.php?nu=PAS3L_443 http://www.abstracts2view.com/pasall/view.php?nu=PAS5L1_459 http://www.abstracts2view.com/pasall/view.php?nu=PAS5L1_459 http://www.abstracts2view.com/pasall/view.php?nu=PAS3L_1843 http://www.abstracts2view.com/pasall/view.php?nu=PAS3L_1843

Table of Contents Feed for the Digital Edition of Managed Care - November 2008

Managed Care - November 2008 Editor’s Memo Contents News and Commentary Legislation & Regulation Letters Medication Management Compensation Monitor Do It Yourself for Less Biomarkers Promise, but Do They Deliver? Oncologists Complain About Drug Payment Consider Blood Pressure Self-Monitoring Q&A: Keep Industry in the Game Formulary Files Plan Watch Tomorrow’s Medicine Outlook Respiratory Syncytial Virus Managed Care Considerations Contents Continuing Education Objectives RSV Disease in the Pediatric Population In the Trenches RSV Infection in the Adult Population Health Plan Medical Director Health Plan Pharmacy Director RSV Issues and Solutions Assessment/Evaluation/Certificate Request Post-Test

Managed Care - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.